Biogen

News

First data with subcutaneous Leqembi, and other CTAD news

Eisai and Biogen have reported data showing that a subcutaneous formulation of its Alzheimer’s disease therapy Leqembi matched the current intravenous version at clearing

News

Biogen claims first with FDA nod for biosimilar Actemra

Biogen says it is the first drugmaker in the US to get FDA approval for a biosimilar of Roche’s $3 billion blockbuster product Actemra.

News

Biogen shuts digital health unit and exits Apple alliance

Biogen has decided to close down its digital health unit, formed just two years ago, as part of a major cost-reduction drive that has already claimed thousands of jobs.

News

Polpharma Bio gets first EU okay for Tysabri biosimilar

Polpharma Biologics has said it is the first company to get approval in the EU for a biosimilar version of Biogen’s blockbuster multiple sclerosis therapy Tysabri.

News

Leqembi approved in Japan, its first ex-US market

Eisai and Biogen now have their second regulatory approval for anti-amyloid therapy Leqembi – in Japan – as a treatment for slowing the progression of Alzheimer’s disease.

News

Grogan named Biogen research chief as reset continues

Chris Viehbacher's efforts to reinvigorate Biogen are continuing to take shape with the appointment of industry veteran Jane Grogan to the position of head of research.

First data with subcutaneous Leqembi, and other CTAD news

Biogen claims first with FDA nod for biosimilar Actemra

Biogen shuts digital health unit and exits Apple alliance

Polpharma Bio gets first EU okay for Tysabri biosimilar

Leqembi approved in Japan, its first ex-US market

Grogan named Biogen research chief as reset continues

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

Biogen

Editor's Picks